References
- World Health OrganizationRegional Office for the Eastern MediterraneanPharmaceutical ProductsGenevaWorld Health Organization2009 Available from: http://www.emro.who.int/health-topics/pharmaceutical-products/index.htmlAccessed October 23, 2015
- JohnstonAHoltDWSubstandard drugs: a potential crisis for public healthBr J Clin Pharmacol201478221824324286459
- DunneSShannonBDunneCCullenWA review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case studyBMC Pharmacol Toxicol201314123289757
- World Health OrganizationWhat are Substandard and Counterfeit Medicines?GenevaWorld Health Organization2009 Available from: http://www.who.int/medicines/services/counterfeit/faqs/QACounter-feit-October2009.pdfAccessed October 21, 2015
- US Food Drug AdministrationFDA Ensures Equivalence of Generic DrugsSilver Spring, MDUS Food and Drug Administration2002 Available from: http://www.fda.gov/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparedness/ucm134444.htmAccessed July 6, 2015
- ThaulSHow FDA approves drugs and regulates their safety and effectivenessCongressional Research Service2012 https://fas.org/sgp/crs/misc/R41983.pdfAccessed July 10, 2015
- CrawfordPFeelyMGubermanAKramerGAre there potential problems with generic substitution of antiepileptic drugs? A review of issuesSeizure200615316517616504545
- SankarRGlauserTAUnderstanding therapeutic equivalence in epilepsyCNS Spectr201015211212320414156
- CockburnRNewtonPNAgyarkoEKAkunyiliDWhiteNJThe global threat of counterfeit drugs: why industry and governments must communicate the dangersPLoS Med200524e10015755195
- ShakoorOTaylorRBBehrensRHAssessment of the incidence of substandard drugs in developing countriesTrop Med Int Health1997298398459315042
- AlmuzainiTChoonaraISammonsHSubstandard and counterfeit medicines: a systematic review of the literatureBMJ Open201338e002923
- AlmuzainiTSammonsHChoonaraIQuality of medicines in Canada: a retrospective review of risk communication documents (2005–2013)BMJ Open2014410e006088
- BennetSThe falsified medicines directive: impacts on API importsSpecialty Chemicals Magazine2013 Available from: http://www.specchemonline.com/articles/view/the-falsified-medicines-directive#.VaeqePlVhHwAccessed July 16, 2015
- Directive 2011/62/EU of the European Parliament and of the Council of 8 June 2011 Available from: http://ec.europa.eu/health/files/eudralex/vol-1/dir_2011_62/dir_2011_62_en.pdfAccessed October 23, 2015
- JiangHWuSLKargerBLHancockWSMass spectrometric analysis of innovator, counterfeit, and follow-on recombinant human growth hormoneBiotechnol Prog200925120721819224592
- CorrealeJChiqueteEMilojevicSFriderNBajuszIAssessing the potential impact of non-proprietary drug copies on quality of medicine and treatment in patients with relapsing multiple sclerosis: the experience with fingolimodDrug Des Devel Ther20148859867
- LonCTTsuyuokaRPhanouvongSCounterfeit and substandard antimalarial drugs in CambodiaTrans R Soc Trop Med Hyg2006100111019102416765399
- World Health OrganizationMedicines: Spurious/Falsely-labelled/Falsified/Counterfeit (SFFC) MedicinesGenevaWorld Health Organization2012 Available from: http://www.who.int/mediacentre/factsheets/fs275/en/Accessed March 1, 2015
- PharmafileDr Reddy’s recalls blood pressure drug2014 Available from: http://www.pharmafile.com/news/188481/dr-reddy-s-recalls-blood-pressure-drugAccessed July 31, 2015
- NeuvonenPJBioavailability and central side effects of different carbamazepine tabletsInt J Clin Pharmacol Ther Toxicol19852342262323997307
- MeyerMCStraughnABJarviEJWoodGCPelsorFRShahVPThe bioinequivalence of carbamazepine tablets with a history of clinical failuresPharm Res1992912161216161488405
- PatelVCordatoDJDiasMBeranRGChanged constitution without change in brand name – the risk of generics in epilepsyEpilepsy Res2012982–326927222030125
- ÁlvarezAAMyslerERuiz de CastillaEMFlores-MurrietaFJHughesJFeijó AzevedoVRecommendations for the regulation of biosimilars and their implementation in Latin AmericaGaBI201433143148
- HomedesNUgaldeAMultisource drug policies in Latin America: survey of 10 countriesBull World Health Organ2005831647015682251
- Alfonso-CristanchoRAndiaTBarbosaTWatanabeJHDefinition and classification of generic drugs across the worldAppl Health Econ Health Policy201513Suppl 1S5S1126091708
- BoretsOGDavydovskaiaMVDeminaTLExperience of using interferon beta-1a biosimilars (Cinnovex and Genfaxon-44) in the Moscow Multiple Sclerosis CenterZh Nevrol Psikhiatr Im S S Korsakova20151152 Vypusk 2 Rasseiannyi skleroz515626081337
- KasatkinDSSpirinNNBoikoANVlasovIVUnified assessment of adverse events of multiple sclerosis disease-modifying drugs.Zh Nevrol Psikhiatr Im S S Korsakova20141142 Vypusk 2 Rasseiannyi skleroz788224662361
- European Medicines AgencyGuideline on the Investigation of BioequivalenceLondonEuropean Medicines Agency2010 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdfAccessed July 1, 2015
- US Food Drug AdministrationGuidance for Industry: Bioequivalence Studies with Pharmacokinetic Endpoints for Drugs Submitted under an ANDASilver Spring, MDUS Food and Drug Administration2013 Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm377465.pdfAccessed August 13, 2015
- World Health OrganizationTechnical Report Series No. 937Multisource (Generic) Pharmaceutical Products: Guidelines on Registration Requirements to Establish InterchangeabilityGenevaWorld Health Organization2006 http://apps.who.int/prequal/info_general/documents/TRS937/WHO_TRS_937__annex7_eng.pdfAccessed September 21, 2015
- US Food Drug AdministrationGuidance for Industry: ANDA Submissions – Content and Format of Abbreviated New Drug ApplicationsSilver Spring, MDUS Food and Drug Administration2014 Available from: http://www.fda.gov/downloads/drugs/guidancecom-plianceregulatoryinformation/guidances/ucm400630.pdfAccessed August 13, 2015
- YuLXJiangWZhangXNovel bioequivalence approach for narrow therapeutic index drugsClin Pharmacol Ther201597328629125669762
- MomperJDRidenourTASchonderKSShapiroRHumarAVenkataramananRThe impact of conversion from Prograf to generic tacrolimus in liver and kidney transplant recipients with stable graft functionAm J Transplant20111191861186721714845
- KlintmalmGBImmunosuppression, generic drugs and the FDAAm J Transplant20111191765176621794082
- CutlerNRPharmacokinetic studies of antipsychotics in healthy volunteers versus patientsJ Clin Psychiatry200162Suppl 51013 discussion 23–2411305842
- ShawSJHartmanALThe controversy over generic antiepileptic drugsJ Pediatr Pharmacol Ther2010152819322477799
- HeldermanJHKangNLegorretaAPChenJYHealthcare costs in renal transplant recipients using branded versus generic ciclosporinAppl Health Econ Health Policy201081616820038194
- GotheHSchallISavernoKThe impact of generic substitution on health and economic outcomes: a systematic reviewAppl Health Econ Health Policy201513Suppl 1S21S3326091709
- BeranRGGeneric substitution in contravention of doctor’s prescriptionsIntern Med J20154510109326429225
- CramerJAGlassmanMRienziVThe relationship between poor medication compliance and seizuresEpilepsy Behav20023433834212609331
- WarrenJBGenerics, chemisimilars and biosimilars: is clinical testing fit for purpose?Br J Clin Pharmacol201375171422574725
- ZunigaLCalvoBBiosimilars: pharmacovigilance and risk managementPharmacoepidemiol Drug Saf201019766166920583204
- CalvoBZunigaLEU’s new pharmacovigilance legislation: considerations for biosimilarsDrug Saf201437191824190573
- DeclerckPJBiosimilar monoclonal antibodies: a science-based regulatory challengeExpert Opin Biol Ther201313215315623286777
- FaulknerMRisk of progressive multifocal leukoencephalopathy in patients with multiple sclerosisExpert Opin Drug Saf201514111737174826394704
- US Food Drug AdministrationGuidance for Industry: Suicidal Ideation and Behavior: Prospective Assessment of Occurrence in Clinical TrialsSilver Spring, MDUS Food and Drug Administration2012 Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM225130.pdfAccessed November 16, 2015
- US Food Drug AdministrationGuidance for Industry: Assessment of Abuse Potential of DrugsSilver Spring, MDUS Food and Drug Administration2010 Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guid-ances/ucm198650.pdfAccessed November 16, 2015
- ChunJHartungHPMechanism of action of oral fingolimod (FTY720) in multiple sclerosisClin Neuropharmacol20103329110120061941
- GrovesAKiharaYChunJFingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapyJ Neurol Sci20133281–291823518370
- European Medicines AgencyICH Guideline M7 on Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic RiskLondonEuropean Medicines Agency2013 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/02/WC500139217.pdfAccessed October 21, 2015
- Garcia-ArietaAInteractions between active pharmaceutical ingredients and excipients affecting bioavailability: impact on bioequivalenceEur J Pharm Sci201465899725236823
- US Food Drug AdministrationGuidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification SystemSilver Spring, MDUS Food and Drug Administration2000 Available from: http://www.gmp-compliance.org/guidemgr/files/3618FNL.PDFAccessed October 21, 2015
- European Medicines AgencyGuideline on Good Pharmacovigilance Practices (GVP): Module V – Risk Management SystemsLondonEuropean Medicines Agency2012 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129134.pdfAccessed July 1, 2015
- Novartis Pharmaceuticals CorporationNDA 22-527. Gilenya (fingoli-mod) 0.5mg capsules: risk evaluation and mitigation strategy (REMS)2015 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/rems/Gilenya_2015-05-14_Full.pdfAccessed October 22, 2015
- US Food Drug AdministrationDrug Safety Communication: Revised Recommendations for Cardiovascular Monitoring and Use of Multiple Sclerosis Drug Gilenya (Fingolimod)Silver Spring, MDUS Food and Drug Administration2015 Available from: http://www.fda.gov/Drugs/DrugSafety/ucm303192.htmAccessed July 3, 2015
- KupermanGCardiac safety profile during first-dose monitoring period of fingolimod (Gilenya) treatment in patients with relapsing remitting MS: data from the Argentinean registry (REAL). Interim resultsNeurology20158414 Supplement P3.250
- International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use harmonised tripartite guideline. Impurities in new drug products Q3B(R2). Current Step 4 version2006 Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q3B_R2/Step4/Q3B_R2__Guideline.pdfAccessed September 21, 2015
- US Food Drug AdministrationQuality by Design for ANDAs: An Example for Immediate-release Dosage Forms Pharmaceutical Development Report Example QbD for IR Generic DrugsSilver Spring, MDUS Food and Drug Administration2012 Available from: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/UCM304305.pdfAccessed October 21, 2015
- The United States Pharmacopeial ConventionStage 6 harmonization. Uniformity of dosage units2011 Available from: http://www.usp.org/sites/default/files/usp_pdf/EN/USPNF/2011-02-25905UNIFOR-MITYOFDOSAGEUNITS.pdfAccessed October 21, 2015